



Press release

Cyberkinetics Inc. completes merger and public listing

Munich/Zug/London, 15 December 2004 – *Global Life Science Ventures (GLSV)* today announced that a first portfolio company financed through its second fund, Cyberkinetics Inc., went public on October 5. After completion of a merger with Trafalgar Ventures, Inc., the new company has been renamed Cyberkinetics Neurotechnology Systems, Inc. and is now listed on the OTC market in the United States (OTC BB: CYKN). The public listing was followed by a successful USD 6 million private financing round on November 4 through a private investment in public equity (PIPE). The funds raised from these transactions will be used to further the company's neural interface systems and develop early stage research programs.

Cyberkinetics Neurotechnology Systems, Inc., is developing innovative devices for the treatment of nervous system dysfunction by combining recent advances in neuroscience, computer science and engineering. The company's first system, BrainGate™, is able to measure and interpret brain signals and translate these signals into useful computer-controlled actions. For example, the initial device allows, for the first time, a patient to communicate with a computer just by the power of his or her thoughts. BrainGate™ is being evaluated in an ongoing pilot study under an Investigational Device Exemption from the U.S. Food and Drug Administration.

Philip Morgan, Venture Partner at GLSV, remarked: "The public listing of Cyberkinetics through a reverse merger is a significant development in the company's history. The merger has quickly put the company in an outstanding position to pursue its pilot clinical trial for BrainGate™ as well as advance its other research and development programs." Hanns-Peter Wiese, Partner, added: "We believe that the merger and listing are important milestones that will allow the company to develop on its impressive track record to date."

GLSV participated through its second fund in the series A private financing round of Cyberkinetics, Inc. in July 2003. To date, eight companies financed through GLS I (seven) and GLSV II (one) are publicly listed.

About Global Life Science Ventures:

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany, Switzerland, and the UK, GLSV is dedicated to providing finance primarily to early-stage groups, originating from universities, scientific institutions or industry, as well as selected later stage companies, including buy-outs. The group currently advises and manages funds greater than €200 million. Up to now, GLSV has financed 30 leading biotechnology companies, eight of which have completed a successful exit through IPO or trade-sale. GLSV has built a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.



Global Life Science Ventures – one team – three locations – global perspective

Germany

GLSV GmbH
Von-der-Tann-Str. 3
D – 80539 München
Tel. +49 (0)89 288 151 0
Fax +49 (0)89 288 151 30
www.glsv-vc.com
mailbox@glsv-vc.com

Switzerland

GLSV AG
Postplatz 1, P.O. 626
CH – 6301 Zug
Tel. +41 (0)41 727 19 40
Fax +41 (0)41 727 19 45

UK

GLSV Ltd.
1, Northumberland Avenue
London WC2N 5BW, UK
Tel. +44 (0)20 89 38 66 92
Fax +44 (0)20 89 38 77 40

For additional information, please contact:

Rochat & Partners

Christophe Lamps
Tel. +41 22 718 37 46
Fax +41 22 786 54 58
E-mail: clamps@rochat-pr.ch